Immix Biopharma Inc <IMMX.OQ> expected to post a loss of 16 cents a share - Earnings Preview
Immix Biopharma Inc IMMX.OQ IMMX.O is expected to report results on August 11 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Immix Biopharma Inc is for a loss of 16 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts had risen by about 23.8% in the last three months.
Wall Street's median 12-month price target for Immix Biopharma Inc is $7.00, about 65.9% above its last closing price of $2.39
This summary was machine generated August 8 at 22:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
BoE August Rate Decision Commentary: Where Next for the Pound?
TradingKey - On 7 August 2025, the Bank of England (BoE) lowered its benchmark interest rate from 4.25% to 4%, aligning with broad market expectations. Notably, the decision sparked significant division within the committee, requiring two rounds of voting to pass.
U.S. GDP, PCE, and Fed Rate Decision Commentary: Will U.S. Stocks Continue to Rise?
TradingKey - On 30–31 July 2025, the United States released its latest GDP and PCE data, while the Federal Reserve announced its interest rate decision during the same period.
Ethereum Price Prediction: Will ETH Extend the Rally? What’s the Future Trend?
Ethereum's impressive 2025 rally has been largely fueled by inflows from spot ETFs and a surge in institutional holdings, signaling growing confidence in its role as a core asset in the crypto market. However, to officially confirm the start of a new bull cycle, ETH must break above the critical $4,
Bitcoin Price Forecast: Trends and Investment Outlook from 2025 to 2030
From $0.01 in 2009 to $120,000+ in 2025, Bitcoin has evolved from obscurity to a globally recognized financial asset. While institutions and governments increasingly embrace it, investors must remain vigilant against volatility, security risks, and scams.
